Lantheus stock dropped 26% post-SPLASH study, highlighting risks in mCRPC drug development and its strategic alliance with POINT Biopharma. SPLASH trial met primary goals but showed underwhelming ...

Detection of mutations in homologous recombination repair (HRR) pathway genes using liquid biopsy in metastatic, castration-resistant prostate cancer (mCRPC) patients without tumor tissue availability ...

Evaluation of time to metastasis (TTM) from prostatectomy and survival in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen deprivation therapy ...

Joseph Wood details his treatment journey with metastatic castration-resistant prostate cancer (mCRPC) and how the journey has impacted his wife and caregiver, Deborah Wood. Alicia Morgans, MD:There ...

AstraZeneca, in collaboration with Merck Sharp & Dohme LLC, is conducting a study titled ‘A Prospective Observational Study to Evaluate Real-world Clinical Outcomes and Characteristics of Patients ...

SAN FRANCISCO -- Adding the PARP inhibitor olaparib (Lynparza) to standard-of-care abiraterone (Zytiga) as initial treatment for metastatic castration-resistant prostate cancer (mCRPC) extended median ...

Clinical or radiologic progression is less likely with abiraterone plus prednisone than cabazitaxel following first-line docetaxel, study finds. Second-line therapy with abiraterone plus prednisone ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that ...

CHICAGO — Men with metastatic castration-resistant prostate cancer previously treated with docetaxel experienced improved radiographic PFS after a regimen of orteronel plus prednisone, according to ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...